Impact of a guaranteed access program to imatinib on the survival of patients with chronic myeloid leukemia
Cancer Causes & Control · 2024
DOI: 10.1007/s10552-024-01912-1 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cancer Causes & Control, 2024. Verfasst von Gilberto Barranco und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Hospital General de México Dr. Eduardo Liceaga, Dr. Eduardo Liceaga Dr. Balmis 148, Doctores, Cuauhtémoc, 06720, Mexico Cit…. Hauptthemen laut MEDLINE: Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Antineoplastic Agents. Die Arbeit nennt 17 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: This work aimed to evaluate the impact of a guaranteed access program to imatinib on the survival of patients with Chronic Myeloid Leukemia. METHODS: We carried out a retrospective, observational, and analytical study of the database of patients diagnosed with Chronic Myeloid Leukemia of the Instituto Nacional de Cancerología and the Hospital General de México Dr. Eduardo to assess overall survival based on guaranteed access or not to imatinib. RESULTS: With an average follow-up of 99 months, all patients' estimated 20-year overall survival was 72% (95% CI, 76-67). A significant difference was found in the 20-year survival probability in favor of patients with guaranteed access 76% (95% CI, 81-71) vs. 61% (95% CI, 69-52) (p < 0.001), in addition to those in which they had better attachment 81.2% (95% CI, 85-76) vs. 44.9% (95% CI, 52-37) (p < 0.001). CONCLUSION: CML is the most frequent chronic leukemia in Mexico. It mainly affects the economically active population (mean age 40), and the prognosis in our country has improved, emulating developed countries; however, the results depend on access to treatment and proper monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Hospital General de México Dr. Eduardo Liceaga, Dr. Eduardo Liceaga Dr. Balmis 148, Doctores, Cuauhtémoc, 06720, Mexico City, Mexico. drgibalampon@gmail.com.
- Department of Hematology, Instituto Nacional de Cancerología, Mexico City, Mexico. drgibalampon@gmail.com.
- Department of Hematology, Instituto Nacional de Cancerología, Mexico City, Mexico.
- Department of Hematology, Hospital General de México Dr. Eduardo Liceaga, Dr. Eduardo Liceaga Dr. Balmis 148, Doctores, Cuauhtémoc, 06720, Mexico City, Mexico.
- Laboratory of Molecular Biology, Hospital General de México Dr. Eduardo Liceaga, Mexico City, Mexico.
- Laboratory of Molecular Biology, Instituto Nacional de Cancerología, Mexico City, Mexico.
ORCID-Profile: Gilberto Barranco
Zitieren
APA
Barranco, G., Vidal, I., Gama, D., Martínez, C., Acosta, B., Ramos, C., Martínez, E., Zazueta, J., Olarte, I., Martínez, A., Cervera, E., Mendoza, I., Arcos, D., & Cruz, J. (2024). Impact of a guaranteed access program to imatinib on the survival of patients with chronic myeloid leukemia. Cancer Causes & Control. https://doi.org/10.1007/s10552-024-01912-1
Vancouver
Barranco G, Vidal I, Gama D, Martínez C, Acosta B, Ramos C, et al. Impact of a guaranteed access program to imatinib on the survival of patients with chronic myeloid leukemia. Cancer Causes & Control. 2024. doi:10.1007/s10552-024-01912-1
BibTeX
@article{Barranco2024,
author = {Barranco, Gilberto and Vidal, Itzel and Gama, Dulce and Martínez, Carlos and Acosta, Brenda and Ramos, Christian and Martínez, Emmanuel and Zazueta, Juan and Olarte, Irma and Martínez, Adolfo and Cervera, Eduardo and Mendoza, Iveth and Arcos, Diana and Cruz, Judith},
title = {Impact of a guaranteed access program to imatinib on the survival of patients with chronic myeloid leukemia},
journal = {Cancer Causes & Control},
year = {2024},
doi = {10.1007/s10552-024-01912-1}
}
EUVIMED